Pharmaceuticals company Dishman Carbogen Amcis announced Q2FY25 results Net Revenue at Rs 7,890.4 million in Q2FY25 up by 34.5% YoY mainly due to increase in commercial sales in the CRAMS segment in Switzerland and India. Carbogen Amcis AG – CRAMS revenue increased by 51.7% YoY in Q2FY25 primarily due to higher commercial sales and also rollover of certain shipment which got pushed to Q2 from Q1FY25. Carbogen Amcis BV– Cholesterol and Vitamin D analogues revenue decreased by 35.7% YoY in Q2FY25 primarily due to lower sales of Cholesterol SF on account of lower margin realizations. DCAL India – NCE APIs and Intermediates revenue increased by 36.9% YoY in Q2FY25 primarily due to increase in commercial sales from Bavla site. DCAL India – Quats & Generics revenue decreased by 20.8% YoY in Q2FY25 primarily due to slowdown in the agrochemical sector. EBITDA Margin at 18.8% in Q2FY25 compared to 10.8% in Q2FY24 due to: Increase in operating margins in CARBOGEN AMCIS – CRAMS segment from 12.2% to 19.7% due to higher volume of commercial sales. Increase in operating margins at Carbogen Amcis BV from 10.1% to 14.7% due to higher sales of vitamin D analogues with higher margins. Increase in operating margins at DCAL India - NCE APIs & Intermediates to 13.9% compared to negative margins in Q2FY24 due to increase in operations in Bavla site. Net Debt excluding lease liabilities was CHF 173 million as on September 30, 2024. Capital expenditure for H1FY25 was approximately USD 15.9 million. Result PDF